Warning letter
National Chemical Laboratories: warning letter of Nov 8, 2023
FDA warning letter 662110 · Office of Pharmaceutical Quality Operations
Key facts
| Reference number | 662110 |
|---|---|
| Company | National Chemical Laboratories |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Nov 8, 2023 |
| Posted date | Nov 21, 2023 |
| Issuing office | Office of Pharmaceutical Quality Operations |
| Product type | Drugs |
| CFR sections cited | 211.22(d), 211.22, 211.34, 211.67(b), 211.84(d)(2), 211.100(a), 211.166(a) |
| Inspection city | Philadelphia |
| Inspection ZIP | 19123 |
| Inspection start date | May 22, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: